Silver Bullet Therapeutics Inc.
This article was originally published in Start Up
The standard of care for osteomyelitis has not changed over the past half century: long-term intravenous antibiotics with multiple agents and doses administered daily and typically lasting a full 12 weeks, followed by oral medications for an additional several months to a year. Silver Bullet Therapeutics Inc. is developing a temporary, implantable silver-eluting implant to fight infection in tandem with IV antibiotics. The company's founders say it should shorten the duration of IV therapy by half.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Look For A Place In Coming Hepatitis C Combo Regimens." features profiles of AiCuris, Avila Therapeutics, Okairos, Viroblock and Zirus. Plus these Start-Ups Across Health Care: Arineta, HemoShear, Hygieia and Silver Bullet Therapeutics.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.